PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bttDove Medical PressThis ArticleSubscribeSubmit a ManuscriptSearchFollowDovepressBiologics: Targets and Therapy
 
Biologics. 2012; 6: 147–154.
Published online Jun 20, 2012. doi:  10.2147/BTT.S24155
PMCID: PMC3395897
Ovarian cancer: emerging molecular-targeted therapies
Carole Sourbier
Rockville, MD, USA
Correspondence: Carole Sourbier, Rockville Pike, Rockville, MD 20852, USA, Email sourbierc/at/gmail.com
Abstract
With about 22,000 new cases estimated in 2012 in the US and 15,500 related deaths, ovarian cancer is a heterogeneous and aggressive disease. Even though most of patients are sensitive to chemotherapy treatment following surgery, recurring disease is almost always lethal, and only about 30% of the women affected will be cured. Thanks to a better understanding of the molecular mechanisms underlying ovarian cancer malignancy, new therapeutic options with molecular-targeted agents have become available. This review discusses the rationale behind molecular-targeted therapies and examines how newly identified molecular targets may enhance personalized therapies for ovarian cancer patients.
Keywords: ovarian cancer, angiogenesis, PI3K/Akt, BRCA, metabolism
Articles from Biologics : Targets & Therapy are provided here courtesy of
Dove Press